Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325240 · ClinicalTrials.gov registry record · Phase 4
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
A Phase 4 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07325240: Recruiting Phase 4 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Mayo Clinic.
NCT07325240 is a Phase 4 study of Ocular Hypertension and Open Angle Glaucoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07325240, a Phase 4 study of Ocular Hypertension and Open Angle Glaucoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).
Primary Outcome
Change in mean IOP from baseline at each time point for Latanoprost
Conditions Studied
Interventions
- DRUG Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
- DRUG Latanoprost 0.005% Ophthalmic Solution
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2027-10 |
| Phase | Phase 4 |
What NCT07325240 shows while recruiting
NCT07325240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution is the first listed.
NCT07325240 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07325240 about?
NCT07325240 is a clinical study titled "24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients". The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG...
What is the current status of trial NCT07325240?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-11-21. Estimated completion is 2027-10.
What conditions does trial NCT07325240 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT07325240?
The interventions under investigation include: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution (DRUG), Latanoprost 0.005% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT07325240?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325240 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07325240's enrollment target sits among peer trials
30 49th of 54 higher than 5 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
-
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 4
-
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
COMPLETED · Phase 4
-
DSLT for Reducing Medication in Glaucoma
RECRUITING
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI